None

Celtic Therapeutics Announces the Appointment of New Partner.

NEW YORK, USA and LAUSANNE, Switzerland – October 29, 2012 – Celtic Therapeutics L.L.L.P., the global private equity firm focused on novel therapeutic product candidates, today announ...

ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D.

Lausanne, Switzerland, 17 July 2012 – ADC Therapeutics (ADCT), the drug development company targeting cancers with antibody-drug conjugate (ADC) “warhead” therapies, today annou...

ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D

ADC Therapeutics (ADCT), the drug development company targeting cancers with antibody-drug conjugate (ADC) “warhead” therapies, today announced the appointment of former Genma...

Celtic Therapeutics Announces the Appointment of New Partner

Celtic Therapeutics L.L.L.P., the global private equity firm focused on novel therapeutic product candidates, today announced that Beth P. Hecht has joined the company as a Partne...

Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs.

New York, USA, Lausanne, Switzerland and London, UK, 26 March 2012 – Celtic Therapeutics Management L.L.L.P. the global private equity firm focused on novel therapeutic product candidates,...

Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates

  London and Lausanne, 6 July 2012 - Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and Switzerland-based ADC Therapeutics Sarl (ADCT)* announce today that they...

None